Resveratrol Modulates Bone Mineral Density and Bone Mineral Content in A Rat Model of Male Hypogonadism.
10.1007/s11655-022-2895-2
- Author:
Hussein F SAKR
1
;
Boudaka AMMAR
2
;
Amira ALKHARUSI
2
;
I AL-LAWATI
2
;
Mahmoud ALKHATEEB
3
;
Basim H ELESAWY
4
Author Information
1. Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, 123, Oman. hsakr@squ.edu.om.
2. Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, 123, Oman.
3. Basic Medical Sciences Department, College of Medicine at King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, 11481, Saudi Arabia.
4. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, 21944, Saudi Arabia.
- Publication Type:Journal Article
- Keywords:
male hypogonadism;
osteoporosis;
receptor activator of nuclear factor-kappa;
resveratrol
- MeSH:
Rats;
Male;
Animals;
Bone Density;
Resveratrol/pharmacology*;
Osteoporosis;
Osteoprotegerin/pharmacology*;
Bone Remodeling;
Hypogonadism;
RANK Ligand/pharmacology*
- From:
Chinese journal of integrative medicine
2023;29(2):146-154
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To determine whether resveratrol (Res) can correct osteoporosis induced in a rat model of male hypogonadism.
METHODS:Thirty-two rats were randomly divided into 4 groups, 8 in each group; 1) a control sham group: underwent a similar surgical procedure for induction of orchiectomy (ORCD) without ligation of any arteries or veins or removal of the testis and epididymis; 2) a control + Res-treated group (Con+Res): underwent sham surgery similar to the control, but was then treated with Res, as described below; 3) an ORCD-induced group: bilateral ORCD surgery as described above, and 4) a ORCD+Res-treated group: bilateral ORCD surgery followed by Res treatment. Res treatment began 4 weeks after ORCD and continued for 12 weeks. After 12 weeks, bone mineral density (BMD) and bone mineral content (BMC) were measured in the tibia and femur of each rat's right hind leg. Blood levels of bone turnover indicators such as deoxypyridinoline (Dpd), N-telopeptide of type I collagen (NTX I), alkaline phosphatase (ALP), and osteocalcin (OC), as well as receptor activator of nuclear factor kappa B (RANK) and osteoprotegerin (OPG) were assessed.
RESULTS:ORCD significantly decreased BMD (P<0.01) and significantly increased bone resorption, manifested by increased RANK. In addition, it inhibited serum levels of OPG and OC. Res treatment after ORCD effectively increased serum levels of bone formation markers such as OPG and OC, compared with testisectomized rats (P<0.05).
CONCLUSION:Res could ameliorate bone loss induced by male hypogonadism, possible via restoration of the normal balance between RANK and OPG.
